Skip to content


  • Poster presentation
  • Open Access

SHARE – workpackage 5: evidence-based recommendations for diagnosis and treatment of kawasaki disease and henoch schönlein purpura

  • 1,
  • 1, 2, 3,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 10,
  • 1,
  • 1,
  • 13,
  • 12 and
  • 2, 14
Pediatric Rheumatology201412 (Suppl 1) :P122

  • Published:


  • Vasculitis
  • Kawasaki Disease
  • Purpura
  • Online Survey
  • Expert Committee


Kawasaki Disease (KD) and Henoch Schönlein Purpura (HSP) are paediatric vasculitides that can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physician experience. Consequently, treatment regimens differ throughout Europe. In 2012, a European initiative called SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimize and disseminate guidelines for diagnosis and management for children and young adults with paediatric rheumatic diseases (PRD) such as KD and HSP within Europe.


To provide evidence-based recommendations for diagnosis and treatment of paediatric vasculitides, specifically KD and HSP.


Evidence based recommendations were developed using evidence drawn from systematic reviews of the literature. An expert committee was formed consisting of paediatric rheumatologists from across Europe with expertise in vasculitis. Preliminary statements regarding recommendations on diagnosis and treatment of KD and HSP were developed. These recommendations were evaluated by the expert committee using an online survey. Those with less than 80% agreement in the online survey were reformulated. Subsequently, all recommendations were discussed at a consensus meeting in Genoa (Italy) in March 2014 using the nominal group technique [1]. Recommendations were accepted if more than 80% agreement was reached.


Evidence supporting recommendations for diagnosis and treatment was extracted from the literature. Subsequently, 53 statements on diagnosis and treatment were formulated based on this evidence and expert opinion and were evaluated in an online survey. After discussion of the statements at the consensus meeting, 29 recommendations for KD and 15 recommendations for HSP were accepted with more than 80% agreement during the meeting. Topics covered were criteria for diagnosis, referral of patients, clinical symptoms, useful laboratory investigations, imaging techniques and treatment.


The SHARE initiative provides recommendations for diagnosis and treatment of paediatric vasculitides and thereby facilitates improvement and uniformity of care for patients throughout Europe. Currently, similar processes are ongoing to add additional recommendations on diagnosis and treatment where consensus to date has not been reached, as well as recommendations regarding the holistic care of patients. As a final result, SHARE will provide standards of minimal care for different PRDs, including KD and HSP, as well as more rare vasculitides (PAN, GPA, MPA, EGPA and TA).

Disclosure of interest

None declared.

Authors’ Affiliations

Wilhelmina Children's Hospital, Utrecht, Netherlands
Alder Hey Children's Hospital, Liverpool, UK
Sophia Children's Hospital, Erasmus Medical Centre, Rotterdam, Netherlands
University Children's Hospital Ljubljana, Ljubljana, Slovenia
Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
General University Hospital, Prague, Czech Republic
The Hospital for Sick Children, Toronto, Canada
Bicêtre University Hospital, Paris, France
Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
Gaslini Children's Hospital, Genoa, Italy
Alder Hey Children’s Hospital, Liverpool, UK
Great Ormond Street Hospital for Children, London, UK
Dept. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey
University of Liverpool, Liverpool, UK


  1. Harvey N, Holmes CA: Nominal group technique: an effective method for obtaining group consensus. Int J Nurs Pract. 2012, 18: 188-94.View ArticlePubMedGoogle Scholar


© de Graeff et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.